Activity Details

0.5 AMA PRA Category 1 Credits
0.5 Contact Hour(s)
Released: June 11, 2018
Expires: June 10, 2019
30 minutes to complete

Provided By

Target Audience

This activity is intended for community oncologists, nurses, pharmacists, and other healthcare professionals who manage NSCLC.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

  • Summarize the indications, efficacy, and safety profiles of recently approved therapies for NSCLC, including EGFR and checkpoint inhibitors
  • Devise treatment selection and drug sequencing strategies that incorporate newer therapies for patients with metastatic NSCLC
  • Identify potential toxicities associated with therapies used for NSCLC

Activity Description

The goal of this activity is to provide expert perspective on frequently asked questions pertaining to the treatment of NSCLC so clinicians gain an enhanced understanding of this disease to make the best possible treatment choices for their patients. AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on NSCLC.

Statement of Educational Need

The treatment of NSCLC has changed significantly as a result of the identification of clinically relevant biomarkers and the development of targeted therapies. Although patient outcomes have improved as a result of treatment advances, metastatic disease is still an important challenge. Knowledge and practice gaps can be seen in several aspects of the treatment of metastatic NSCLC, such as how to integrate new therapies into practice, manage toxicities associated with new therapies, and make best use of a shared decision-making approach to treatment.


David S. Ettinger, MD, FACP, FCCP
Alex Grass Professor of Oncology
Professor of Medicine
Professor of Radiation Oncology and Molecular Radiation Sciences
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Disclosure of Conflicts of Interest

AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

David S. Ettinger, MD, FACP, FCCP, serves(d) as an advisor/consultant for:
BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb Co; Eli Lilly and Co; Genentech, Inc; Golden Biotechnology Corporation; and Guardant Health, Inc.

The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The following AXIS planners and managers, Linda-Gracie-King, MS; Jocelyn Timko, BS; Kristen Baileys, RN, MSN, CRNP, OCN; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.

Accreditation Statement

Accreditation Council for Pharmacy EducationIn support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Credit Designation for Physicians
AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education credit. JA4008106-0000-18-017-H01-P

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Method of Participation and Request for Credit

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. Pharmacists – your record will be loaded to CPE Monitor.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

AXIS Contact Information

For information about the certification of this activity, please contact AXIS at

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.